How does KRAS mutation affect treatment options for Ovarian Cancer
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
KRAS Mutations and Ovarian Cancer Treatment
I appreciate your question about KRAS mutations in ovarian cancer. However, I need to be transparent about an important limitation: the medical guidelines and evidence I have access to focus primarily on pancreatic cancer, colorectal cancer, and lung cancer—not ovarian cancer specifically.
What I Can Tell You About KRAS Generally
KRAS mutations are found in many cancer types and act like a "stuck switch" in cancer cells. According to the sources available to me, KRAS is present in:
- ~90% of pancreatic cancers
- ~40% of colorectal cancers
- ~25% of lung adenocarcinomas
When KRAS is mutated, it gets "stuck in the on position," continuously sending growth signals to cancer cells.
The Challenge with Ovarian Cancer Specifically
The evidence I have doesn't include NCCN Guidelines for Ovarian Cancer or ASCO Guidelines specific to ovarian cancer with KRAS mutations. This is a significant gap because ovarian cancer treatment approaches may differ substantially from other cancer types.
What You Should Do
I strongly recommend discussing KRAS status with your oncology team, specifically asking:
- What is my specific KRAS mutation type? (G12C, G12D, G12V, etc. - different mutations have different treatment implications)
- Are there targeted therapies available for my mutation in ovarian cancer?
- What clinical trials might be relevant for my KRAS status?
- How does my KRAS status affect my treatment plan compared to KRAS wild-type (non-mutated) ovarian cancer?
- Should I pursue genetic testing if I haven't already?
Where to Find Ovarian Cancer-Specific Information
For authoritative ovarian cancer guidelines, I recommend:
- NCCN Guidelines for Ovarian Cancer (nccn.org)
- American Cancer Society ovarian cancer resources
- SGO (Society of Gynecologic Oncology) guidelines
- Your cancer center's tumor board, which can review your specific molecular findings
Your oncologist will have access to the latest ovarian cancer-specific evidence about KRAS mutations and can explain how this finding applies to YOUR individual case.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Ovarian Cancer (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with treatment for Ovarian Cancer patients
Have your records handy? Upload them for a deeper, personalized analysis →